GOG 3043 Eligibility

Inclusion

1) Patient must have histologically confirmed uterine cervical adenocarcinoma (usual/classic/NOS),
squamous cell carcinoma, or adenosquamous carcinoma (includes glassy cell).
2) Patient must be FIGO Stage IA2, IBI, IB2 (2018 staging) uterine cervical cancer without evidence of
definitive parametrial, vaginal, nodal or distant metastases on exam or imaging.
3) Patient must have uterine size <12 cm AND felt to be appropriate for vaginal delivery of specimen
per investigator.
4) Patient must be suitable surgical candidate with preoperative assessments such as labs and EKG
performed per institutional standard.
5) Patient must be age 18 years or older.
6) Patient must have ECOG performance status 0-1.
7) Patient must have signed an approved informed consent and authorization permitting the release of
personal health information.

Exclusion

1) Patients with any uterine cervical cancer tumor histology other than those listed above, specifically
excluding the following histologies: neuroendocrine, other adenocarcinoma (gastric type,
endometrioid, clear cell, serous, signet ring, minimal deviation).
2) Patients with FIGO stage 1A1, IB3, II-IV (2018 staging).
3) Patient with inability to obtain MRI.
4) Patients with tumor size ≥4cm or with definite evidence of vaginal/parametrial involvement on MRI
(if MRI findings are not definitive, then clinical examination must also reveal parametrial or vaginal
extension).
5) Patients with evidence of metastatic disease (imaging or histologically positive lymph nodes).
6) Patients with a history of prior pelvic or abdominal radiotherapy.
7) Patients with a prior malignancy within < 5 years from enrollment with the exception of nonmelanoma
skin cancer.
8) Patients who are unable to withstand prolonged lithotomy or steep Trendelenberg.
9) Patient compliance and geographic proximity that do not allow adequate follow-up.
10) Patients with poorly controlled HIV with CD4 counts <500.